Cargando…
Randomized, open-label, blinded-endpoint, crossover, single-dose study to compare the pharmacodynamics of torasemide-PR 10 mg, torasemide-IR 10 mg, and furosemide-IR 40 mg, in patients with chronic heart failure
PURPOSE: Diuretics are the primary treatment for the management of chronic heart failure (HF) symptoms and for the improvement of acute HF symptoms. The rate of delivery to the site of action has been suggested to affect diuretic pharmacodynamics. The main objective of this clinical trial was to exp...
Autores principales: | Ballester, Maria Rosa, Roig, Eulàlia, Gich, Ignasi, Puntes, Montse, Delgadillo, Joaquín, Santos, Benjamín, Antonijoan, Rosa Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532344/ https://www.ncbi.nlm.nih.gov/pubmed/26273191 http://dx.doi.org/10.2147/DDDT.S86300 |
Ejemplares similares
-
Population Pharmacokinetics and Pharmacodynamics Modeling of Torasemide and Furosemide After Oral Repeated Administration in Healthy Dogs
por: Pelligand, Ludovic, et al.
Publicado: (2020) -
Pharmacokinetic and pharmacodynamic properties of orally administered torasemide in healthy cats
por: Roche‐Catholy, Marine, et al.
Publicado: (2022) -
Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers
por: Muñoz, Jose, et al.
Publicado: (2018) -
Short‐Term Efficacy and Safety of Torasemide and Furosemide in 366 Dogs with Degenerative Mitral Valve Disease: The TEST Study
por: Chetboul, V., et al.
Publicado: (2017) -
Commentary: Is Torasemide a Potential Agent in the Treatment of Autism?
por: Machado, Sergio, et al.
Publicado: (2023)